Response to ICRFm1 59 in cell lines resistant to cleavable complex-forming topoisomerase 11 inhibitors
1997

Study of Drug Resistance in Cancer Cell Lines

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): SL Davies, J Bergh, AL Harris, ID Hickson

Primary Institution: Imperial Cancer Research Fund Laboratories, University of Oxford

Hypothesis

The study investigates the relationship between gene expression and resistance to topoisomerase II inhibitors in cancer cell lines.

Conclusion

The resistance mechanisms for cleavable complex-forming topoisomerase II inhibitors and ICRF-159 are distinct, with some cell lines showing collateral sensitivity to ICRF-159.

Supporting Evidence

  • Overexpression of P-glycoprotein and MRP did not confer resistance to ICRF-159.
  • Marked down-regulation of topoisomerase IIa was associated with collateral sensitivity to ICRF-159.
  • Cell lines selected for resistance to cleavable complex-forming topo II inhibitors were not cross-resistant to ICRF-159.

Takeaway

This study looked at how certain cancer cells resist drugs and found that some cells can actually be more sensitive to a different drug.

Methodology

The study used various human cancer cell lines and assessed their sensitivity to ICRF-159 through clonogenic and growth inhibition assays.

Limitations

The study does not provide a consistent pattern of altered topoisomerase II gene expression across all resistant cell lines.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication